A Study to Assess A Change in Disease Activity and Adverse Events of Intravenous Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Adult Participants With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant

NCT07095452 · readout ≤ 5,643 d

Sponsored by AbbVie (industry) · ABBV — their whole pipeline →. With IFM (Intergroupe Français du Myélome); PETHEMA (Program for the Study and Treatment of Haematological Malignances).

Phase

Phase 2/3

Status

Recruiting

Study type

Interventional

Design

Randomized · None · Treatment

Enrollment

660estimated

Sites

Countries

France, Japan, Spain +1

Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →

Source: ClinicalTrials.gov, retrieved 2026-08-19

Dates

each axis at the precision it was filed, with the registry's own basis

Date

Filed

Basis

What it is

Start

2026-01-08

actual

When the study began enrolling

Primary completion

Jan 2042

estimated

The date the last participant is measured for the primary outcome — the readout window

Study completion

Jan 2042

estimated

The whole study's end, after follow-up

First posted

2025-07-31

actual

When this record first appeared on the registry

Results posted

—

When the sponsor posted results to the registry

Record updated

2026-06-11

actual

The sponsor's own last edit to this record — every projection above is as current as this date

What it studies

Condition

Multiple Myeloma

Interventions

Drug: Etentamig
Drug: Lenalidomide
Drug: Daratumumab
Drug: Dexamethasone
Drug: Dexamethasone

Primary outcomes

what the primary-completion date above is the date OF

Phase 2 and 3: Percentage of Participants with Adverse Events (AE)s

measured Up to Approximately 16 Years

Phase 2: Change in Clinical Activity

measured Up to Approximately 52 weeks

Phase 3: Minimal Residual Disease (MRD) Negative CR Rate

measured Up to Approximately 52 weeks

Phase 3: Progression-Free Survival (PFS)

measured Up to Approximately 130 Months

Permalink · ABBV's whole pipeline · Catalyst calendar · Every registered study · What changed